MedTrace Logo

Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis

NCT03320434 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2022-10-17

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy and safety of two concentrations of PRT-2761 as a topical ophthalmic solution for the treatment of the signs and symptoms of acute and chronic allergic conjunctivitis.

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

PRT-2761 0.5%

Six drops in each eye over a 17 day period.

DRUG

PRT-2761 1%

Six drops in each eye over a 17 day period.

DRUG

Patanol

Six drops in each eye over a 17 day period.

DRUG

Pred-forte

Four drops in each eye over a 3 day period.

DRUG

PRT-2761 0%

Six drops in each eye over a 17 day period.

Sponsors & Collaborators

  • ORA, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-13
Primary Completion
2018-02-16
Completion
2018-02-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03320434 on ClinicalTrials.gov